Millennium Management
UNCY icon

Millennium Management’s Unicycive Therapeutics UNCY Stock Holding History

Millennium Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.21M Buy
1,399,348
+384,505
+38% +$2.52M ﹤0.01% 2250
2025
Q4 		$5.86M Buy
+1,014,843
New +$5.42M ﹤0.01% 2834

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management's UNCY Position: Q1 2026 in Review

Millennium Management increased its Unicycive Therapeutics (UNCY) stake by 38% in Q1 2026, buying an estimated $2.52M and bringing the position to 1,399,348 shares worth $9.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Millennium Management first reported a position in UNCY in Q4 2025 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Millennium Management held 1,399,348 shares of Unicycive Therapeutics worth $9.21M as of Q1 2026.
  • Millennium Management bought 384,505 Unicycive Therapeutics shares in Q1 2026, an estimated $2.52M.
  • Unicycive Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2250 holding.
  • Millennium Management first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.